// App-Quantinova.ai

OC 12.1 : Efficacy and Safety of Dabigatran Etexilate for Treatment of Venous Thromboembolism in Paediatric Patients Aged from Birth to < 2 Years - Results of the DIVERSITY Trial

Researchers

Presenter

  • J. Halton

Principal Investigators

  • M. Luciani

  • L. Bomgaars

  • E. Chalmers

  • L. Mitchell

  • I. Nurmeev

  • A. Sharathkumar

  • P. Svirin

  • K. Gorbatikov

  • I. Tartakovsky

  • M. Simetzberger

  • F. Huang

  • Z. Sun

  • J. Kreuzer

  • S. Gropper

  • P. Reilly

  • M. Brueckmann

  • M. Albisetti

Medical Centers

  • Children's Hospital of Eastern Ontario and University of Ottawa, Ottawa, ON, Canada,

  • Hospital for Sick Children, University of Toronto, Toronto, ON, Canada

  • Pediatric Hospital Bambino Gesù, Pediatric Hematology/Oncology, Rome, Italy

  • Texas Children's Cancer Center, Baylor College of Medicine, Department of Pediatrics, Houston, United States

  • Royal Hospital for Sick Children, Glasgow, United Kingdom

  • Pediatric Hospital, Kazan, Republic Tatarstan, Russian Federation

  • University of Iowa Hospitals and Clinics, Stead Family Department of Pediatrics, Iowa City, United States

  • Municipal Children's Hospital 'Morozovskaya', Pediatric Hematology Department, Moscow, Russian Federation

  • Regional Hospital #1, Pediatric Cardiovascular Surgery, Tyumen Region, Russian Federation

  • Boehringer Ingelheim International GmbH, Therapeutic Area Cardiovascular Medicine, Ingelheim am Rhein, Germany

  • Boehringer Ingelheim RCV GmbH & Co. KG, Department of Clinical Development, Wien, Austria

  • Boehringer Ingelheim Pharmaceuticals, Inc, Translational Medicine and Clinical Pharmacology, Ridgefield, United States

  • Boehringer Ingelheim Pharmaceuticals, Inc., Biostatistics and Data Sciences, Ridgefield, United States

  • Boehringer Ingelheim Singapore Pte. Ltd, Regional Operating Unit South East Asia and South Korea, The Concourse, Singapore

  • Boehringer Ingelheim International GmbH, Therapeutic Area Cardiovascular Medicine, Ingelheim am Rhein, Germany

  • Boehringer Ingelheim Pharmaceuticals, Inc., Therapeutic Area Cardiovascular Medicine, Ridgefield, United States

  • University Children's Hospital, Hematology Department, Zürich, Switzerland

Locations

  • Canada

  • Italy

  • United States

  • United Kingdom

  • Russia

  • Germany

  • Austria

  • Singapore

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • Pulmonary/Respiratory Diseases

  • Cardiovascular (CVS)

  • Blood/haematological Diseases

Disease

  • Venous thrombosis

Biomarkers

  • N/A

Drug/Treatment

  • Heparin

  • Pradax

  • Heparin

Outcome

  • N/A

Study Design

  • Randomized

  • Open Label

  • Multicenteric

  • Controlled

Phase

  • II

Study Id's

  • NCT01895777

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved